Immune Checkpoint Inhibitor Can Reduce HCV-RNA without Liver Damage.
Intern Med
; 59(18): 2245-2248, 2020 Sep 15.
Article
en En
| MEDLINE
| ID: mdl-32522918
ABSTRACT
Recently, immune checkpoint inhibitors (iCIs) have been used to treat cancers. Once some of the iCIs for the treatment of hepatocellular carcinoma (HCC) are certified in clinical trials, they are likely be administered to HCC patients with hepatitis C virus (HCV). However, the immunopathogenesis of HCV after the administration of iCIs has not been clarified. We experienced a lung cancer patient with HCV infection treated by nivolumab, programmed cell death 1 (PD-1) antibody. HCV-RNA gradually decreased after the start of nivolumab treatment. However, no increase in transaminase was observed during the decline of HCV-RNA. It was thought that HCV-specific cytotoxic T lymphocytes (CTLs) were activated by iCIs.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
/
2_ODS3
/
4_TD
/
6_ODS3_enfermedades_notrasmisibles
Problema de salud:
1_doencas_nao_transmissiveis
/
2_enfermedades_transmissibles
/
2_muertes_prematuras_enfermedades_notrasmisibles
/
4_hepatitis
/
6_digestive_diseases
/
6_other_respiratory_diseases
/
6_trachea_bronchus_lung_cancer
Asunto principal:
ARN Viral
/
Hepacivirus
/
Nivolumab
/
Inhibidores de Puntos de Control Inmunológico
/
Neoplasias Pulmonares
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Intern Med
Asunto de la revista:
MEDICINA INTERNA
Año:
2020
Tipo del documento:
Article
País de afiliación:
Japón